Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20485137 | 0.85 | KMT2A (0.51) | TSHRHPGDKMT2AMEN1NPC1 | |
| SCHEMBL15670806 | 0.85 | CYP2D6 (0.46) | TSHRL3MBTL1ALDH1A1MAPTHPGD | |
| SCHEMBL10734245 | 0.83 | TSHR (0.49) | TSHRL3MBTL1ALDH1A1MAPTHPGD | |
| SCHEMBL11787133 | 0.81 | ALDH1A1 (0.48) | TSHRL3MBTL1ALDH1A1MAPTHPGD | |
| SCHEMBL11455228 | 0.81 | TSHR (0.59) | TSHRL3MBTL1ALDH1A1MAPTHPGD | |
| SCHEMBL16274031 | 0.81 | TSHR (0.59) | TSHRL3MBTL1ALDH1A1MAPTHPGD | |
| SCHEMBL8938798 | 0.80 | TSHR (0.58) | TSHRL3MBTL1ALDH1A1MAPTHPGD | |
| SCHEMBL11262851 | 0.78 | TSHR (0.55) | TSHRL3MBTL1ALDH1A1MAPTHPGD | |
| Valine SCHEMBL9830598 | 0.77 | SLC7A5 (0.52) | TSHRL3MBTL1ALDH1A1MAPTHPGD | |
| SCHEMBL2791083 | 0.77 | TSHR (0.64) | TSHRALDH1A1MAPTHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-1135796-A | — | — | None | — | — | JP | disclosed |
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | Lee Moffitt Cancer Center and Research Institute, Inc. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-07-20 | — | — | US | disclosed |
| CN-109153644-B | Small molecules against CEREBLON to enhance effector T cell function | H·李·莫菲特癌症中心研究有限公司 | 2022-10-21 | — | — | CN | disclosed |
| US-11395820-B2 | Small molecules against cereblon to enhance effector t cell function | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-07-26 | — | — | US | disclosed |
| US-20210177825-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2021-06-17 | — | — | US | disclosed |
| EP-3429996-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. Lee Moffitt Cancer Center And Research Institute, Inc. (US) | 2019-01-23 | — | — | EP | disclosed |
| CN-109153644-A | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H·李·莫菲特癌症中心研究有限公司 | 2019-01-04 | — | — | CN | disclosed |
| WO-2017161119-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2017-09-21 | — | — | WO | disclosed |
| EP-0315494-B1 | Process for preparation of peptide synthons | RHONE POULENC CHIMIE (FR) | 1993-12-08 | — | — | EP | disclosed |
| EP-0318338-B1 | Process for the preparation of peptide synthons | RHONE POULENC CHIMIE (FR) | 1993-12-08 | — | — | EP | disclosed |
| US-5138037-A | Process for preparing peptide synthons | RHONE-POULENC CHIMIE (FR) | 1992-08-11 | — | — | US | disclosed |
| US-5077387-A | PROCESS FOR PREPARING PEPTIDE SYNTHONS | RHONE-POULENC CHIMIE (FR) | 1991-12-31 | — | — | US | disclosed |
| EP-0318338-A1 | Process for the preparation of peptide synthons | RHONE-POULENC CHIMIE (FR) | 1989-05-31 | — | — | EP | disclosed |
| JP-H01135796-A | PRODUCTION OF SYNTHETIC PEPTIDE | RHONE POULENC CHIM | 1989-05-29 | — | — | JP | disclosed |
| EP-0315494-A1 | Process for preparation of peptide synthons | RHONE-POULENC CHIMIE (FR) | 1989-05-10 | — | — | EP | disclosed |
| US-4690938-A | Anti-hypertensive agents | UNIVERSITY OF MIAMI (US) | 1987-09-01 | — | — | US | disclosed |
| EP-0009898-B1 | NOVEL ANTI-HYPERTENSIVE MERCAPTOACYLAMINO ACID DERIVATIVES, THEIR PREPARATION AND USE | UNIVERSITY OF MIAMI (US) | 1983-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | CRBN, CD4, ICOS | TSHR 1705/4885L3MBTL1 3277/4885ALDH1A1 2373/4885 |
| US-11395820-B2 | Small molecules against cereblon to enhance effector t cell function | CD4, GZMB, CRBN | TSHR 4198/4885L3MBTL1 2252/4885ALDH1A1 4134/4885 |
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | CD4, CRBN, GZMB | TSHR 4274/4885L3MBTL1 3391/4885ALDH1A1 4309/4885 |
| US-20210177825-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | CD4, GZMB, CRBN | TSHR 4198/4885L3MBTL1 2252/4885ALDH1A1 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.